Pharsight

Gavreto patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10030005 BLUEPRINT MEDICINES Inhibitors of RET
Nov, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 BLUEPRINT MEDICINES RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)

US11872192 BLUEPRINT MEDICINES RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(14 years from now)

Gavreto is owned by Blueprint Medicines.

Gavreto contains Pralsetinib.

Gavreto has a total of 3 drug patents out of which 0 drug patents have expired.

Gavreto was authorised for market use on 04 September, 2020.

Gavreto is available in capsule;oral dosage forms.

Gavreto can be used as treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test, treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Drug patent challenges can be filed against Gavreto from 04 September, 2024.

The generics of Gavreto are possible to be released after 03 April, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2025
Orphan Drug Exclusivity(ODE-341) Dec 01, 2027
Orphan Drug Exclusivity(ODE-340) Dec 01, 2027
Orphan Drug Exclusivity(ODE-318) Sep 04, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: 04 September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...

Dosage: CAPSULE;ORAL

More Information on Dosage

GAVRETO family patents

Family Patents